MTOR and glioma: Previously, CLK1 could modulate the chemoresistance of glioma cells via glycolytic signaling mediated by AMPK/mTOR/HIF-1α (45) as well as participating in modulating the splicing process of gastric cancer, serving as an underlying therapeutic target against this malignancy (46).